Our Esteemed Sponsors

On 09th June 2020, the refractive lasers division of ZEISS announced that surgeons have completed performing 3 million SMILE® procedures. More than 1000 clinics worldwide now offer SMILE® which is among the most preferred LVC procedure in contemporary times. Zeiss celebrated 1 million procedures in September 2017 and 2 million in May 2019, the journey from 2 million to 3 million was relatively faster signifying the popularity that SMILE® is gaining worldwide. Due to on-going pandemic threat, many patients are opting for LVC procedures to avoid the chances of infection while using contact lenses. While LVC is helping patients to reduce chances of infection, the surgeons need to consider their safety as well; while performing surgery.
The aerosols produced during the refractive surgery are believed to be potential source of infection. In order to assess the extent of aerosols generated during various refractive procedures and to invent ways and measures for overcoming the same, a team from Narayana Nethralaya performed an independent study that comprised of series of experiments called APPEAR (Aerosol Projectile Prediction Experimental & Applied Research). The experiments were carried out with support from Indian Institute of Science, Bengaluru. In the first episode of their series, the team found out that no visible aerosols were produced during SMILE® procedure as compared to blade LASIK. The use of micro keratome and other blades produce considerable amount of aerosols which spreads to a farther extent on surgeon's side, hence posing a higher risk of infection. Thus, bladeless procedures like SMILE® turn out to be an ideal mode of treatment for both patients and performing surgeons amid the current pandemic crisis.

Novartis is reimagining the treatment and prevention of visual impairment and blindness. We aim to develop life-changing pharmaceuticals and transformative technologies for diseases and conditions from front to back of the eye.

From a humble beginning in 1983, Sun Pharma has grown to emerge as India's No.1 pharmaceutical company selling over 2000 products in more than 100 countries.

• We are the world's 4th largest speciality generic pharmaceutical company.
• We develop high quality, affordable medicines trusted by healthcare professionals & patients in 100 countries across 5 continents.
• Our passion for quality goes beyond business.
• A multi-cultural team of more than 30000 employees are our most valuable asset.
• Our product offerings have the hallmark of technology-based differentiation.

Scientific innovation drives progress and curious minds discover new solutions that were once only imagined. It is the society for all our products and services. We generate new insights, invest deeply in R&D, and collaborate with scientists around the world. To achieve our goal of providing a spectacle free vision, we collaborate with the brightest around the world, gaining insights from patients and clinicians, and translating those insights into improvements in products, patient care, and ultimately life itself.

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.